Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? – a systematic review by unknown
a SpringerOpen Journal
Oluwagbemiga et al. SpringerPlus 2012, 1:83
http://www.springerplus.com/content/1/1/83REVIEW Open AccessSeventeen years after BRCA1: what is the BRCA
mutation status of the breast cancer patients in
Africa? – a systematic review
Lawal AbdulRazzaq Oluwagbemiga1*, Atoyebi Oluwole1 and Adesunkanmi AbdulRasheed Kayode2Abstract
With the discovery of the BRCA1 gene and other genetic mutations associated with breast cancer, it has been
established that hereditary mutations account for up to 5% of patients presenting with breast cancer.
We performed a systematic review of English Language Literature to determine the role of BRCA1 and BRCA2 gene
mutations in African breast cancer patients. PUBMED and AJOL database were searched for publications addressing
Breast Cancer and BRCA1 and BRCA2 genes. PUBMED was searched using the following words in various
combinations; ‘Breast Cancer’, ‘BRCA1’, ‘BRCA2’, ‘BRCA’, ‘Genes’, ‘Cancer Genes’, and ‘Africa’.
16 studies fulfilled the study criteria up till December 2011. The studies were from North Africa (NA) and
Sub-Saharan Africa (SSA).
A total of 9 studies were found evaluating 752 (352 repeated Zhang J (2010)) patients from SSA. Three studies (144
patients) evaluated all the coding regions of both BRCA1 and BRCA2 while 2 studies (571 patients) evaluated part(s)
of BRCA1 and one (20 Patients) evaluated part(s) of BRCA2, one re-evaluated the whole of the BRCA1 gene in a
previous sub-set of patients, while one (16 patients) evaluated parts of both BRCA1 and BRCA2.
In North Africa, 6 studies evaluated 374 patients, with 4 studies (219 patients) evaluating the whole of the BRCA1
and BRCA2 genes while two (155 patients) studies evaluated only parts of both BRCA1 and BRCA2, with one of the
studies evaluating the whole of the BRCA1 gene in a subset (24 patients).
Due to this paucity of well powered population based studies evaluating the influence of BRCA genetic mutations
in breast cancer patients in Africa, there is a need to perform well powered studies and population screening to
determine the impact of germ line mutations in the Breast Cancer patient in Africa before any categorical
statements can be made with respect to their BRCA status.
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Epidemiology of breast cancer
Breast cancer is the most common malignancy affecting
women worldwide. According to GLOBOCAN there were
1.38 million new cases of breast cancer in the world in
2008, with a corresponding mortality of 458,000. In
Africa, over the same time period, there were 68,000 new
cases with 37,000 deaths documented, although this pro-
bably represents a gross underestimation due to incom-
plete case ascertainment and reporting Adesunkanmi et al.* Correspondence: razzaklawal@yahoo.com
1Department of Surgery, College of Medicine of the University of Lagos,
Lagos, Nigeria
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reproduction in any medium, provided the orig(2006). In 2010, the World Health Organisation (WHO)
estimated that there would be 97,743 new breast cancer
cases in Africa, with an estimated mortality of 52,855
IARC (2011).
The reportedly lower incidence of breast cancer in Africa
may be explained by lower life expectancy, incomplete rec-
ord keeping and paucity of epidemiological studies and in-
complete case ascertainment. In addition, peculiarities in
the presentation of breast cancer in Africa may limit de-
tection Adesunkanmi et al. (2006). These include an ap-
parently younger age and later stage at presentation with
more aggressive tumour characteristics Adesunkanmi et al.
(2006). The late presentation which may be a consequence. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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the more aggressive nature of breast cancer in Africa.
The cause(s) of breast cancer remain largely unknown,
though several risk factors have been characterised. The
most important factors are the age of the patient and
the effect of female sex hormones. Thus early menarche,
late menopause and nulliparity all confer an increased
risk of breast cancer. Breast feeding is noted to be protec-
tive while ingestion of exogenous female sex hormones is
a risk factor for breast cancer.
A positive family history of breast cancer is known to
increase the risk of breast cancer. However, it was only
in 1990, based on the results of linkage analysis per-
formed by Hall et al. (1990) that firm evidence was pro-
vided for the existence of at least one hereditary breast
cancer gene. Miki et al described the first germ line mu-
tation known to confer increased risk of breast cancer in
1994, labelled BRCA1 Miki et al. (1994). Shortly there-
after, a second germ line mutation associated with increa-
sed risk was also identified and named BRCA2 Wooster
et al. 1995). Subsequently, several susceptibility genes have
been associated with breast cancer. These genes confer
‘high-risk’ and ‘low to moderate risk’ of breast cancer.
The high-risk breast cancer susceptibility genes include
BRCA1, BRCA2, PTEN, TP53, LKB1/STK11 and CDH1,
with relative lifetime risks higher than 4 (but generally
much higher at young ages). The CHEK2, TGFβ1, CASP8
and ATM genes belong to the ‘low to moderate-risk’ breast
cancer susceptibility genes Oldenburg et al. (2007).
BRCA1 mutation carriers have a 30% risk of develo-
ping ovarian cancer during their lifetime Whittemore
et al. (1997) and a 50–80% risk of developing breast cancer
before the age of 70 years Deng (2006). BRCA1 is mapped
to chromosome 17q21 Adesunkanmi et al. (2006); it
contains 24 exons and encodes a protein of 220 kDa,
composed of 1863 amino acids Chen et al. (1996). The
second breast cancer susceptibility gene, BRCA2, is
localized on the long arm of chromosome 13. BRCA2 is
also a large gene, with 27 exons that encode a protein
of 380 kDa, composed of 3418 amino acids Bertwistle
et al. (1997).
Risk-associated truncation mutations are found through-
out the entire BRCA1 coding sequence Linger & Kruk
(2010). The majority of risk-associated mutations are fra-
meshift or nonsense mutations that result in a premature
stop codon and truncated protein product (NIH Breast
Cancer Information Core Database, http://research.nhgri.
nih.gov/bic/). Both BRCA1 and BRCA2 are thought to act
as classical tumour suppressor genes and the loss of their
cellular functions is thought to occur through bi-allelic in-
activation. Carriers of mutations have one germline hit (the
inherited mutated copy of BRCA1) and, in the tumour, a
second somatic hit usually through the loss of heterozygo-
sity Deng (2006; Collins et al. 1995).A determination of BRCA genetic mutational status
will go a long way towards advice on prophylaxis for
breast cancer. The data on BRCA gene mutations in
Africans is sparse. The mutational spectrum of BRCA1/
2 in African Americans has not been as well characte-
rized as that of Caucasians Ferla et al. (2007).
The knowledge base about the various genetic muta-
tions in the BRCA genes of people of African origin is
scattered in diverse small pockets of articles. The aim of
this study is to collate all these data and present them in
a single review in order to better characterise the genetic
mutational spectrum of the indigenous African people.
Method
Data on breast cancer genetics in Africans was obtained
via a literature search. The key words were “Breast Can-
cer” and “Africa” with “Genes”, “BRCA Genes”, “BRCA1”
and “BRCA2” in different combinations. The databases
searched were PubMed, African Journals Online (AJOL),
the WHO HINARI database, and Ptolemy (University of
Toronto library). Only articles published in English were
included. References of relevant articles were also revie-
wed for additional literature. Studies combining and/or
comparing Africans with other ethnicgroups were inclu-
ded but only the data of the Africans analysed were in-
cluded in this review. Studies done outside Africa but
which studied an indigenous African people were included.
Specific information retrieved were: type of study, num-
ber of exons evaluated, number, type and classification of
mutations.
Result
BRCA1 and BRCA 2 mutations
Sub Saharan African (SSA)
In 1997, Stoppa-Lyonnet Stoppa-Lyonnet et al. (1997)
evaluated the whole of the BRCA 1 gene and reported a
case of frameshift truncating BRCA1 mutation (926ins10)
in a Breast Ovarian Cancer family from Ivory Coast.
Yawitch et al. (2000) evaluated 206 black South African
women for 185delAG in exon 2, 4184del4, 943ins10 and
1832deI5 in exon 11, and 5382insC in exon 20, and
Met1775Arg in exon 21 mutations in BRCA1. Eleven of
these patients had a family history of Breast cancer. None
of these mutations were found in any of the patients
studied.
Gao Q et al. (2000) screened 70 young African breast
cancer patients with early onset breast cancer in Ibadan,
Nigeria. Only one of the patients had a family history of
breast cancer. All the regions of the BRCA1 and BRCA2
genes were analysed. Eighteen (23%) of the patients had
mutations. Three truncating mutations (2 BRCA1 and 1
BRCA2) were detected. Twenty four non truncating
mutations (4 BRCA1 and 20 BRCA2) were also detected
in this cohort.
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cancer (< 40 years) patients in Nigeria. Twenty nine
(74%) patients carried a genetic variation in BRCA1 (4
variants), BRCA2 (30 variants) or both genes. How-
ever, they found only 1 (3034del4) truncating muta-
tion located on exon 11 of BRCA2. The rest were either
unclassified variants or polymorphisms. They went fur-
ther to test the clinical significance of their finding by
examining the BRCA genes of 74 unaffected Nigerians.
Five of 13 BRCA2 variations expected to result in de-
leterious amino acid substitutions were not found in
the controls.
A truncating mutation in BRCA1 (Y101X (422 T > G),
exon 7) previously identified in Nigerian Breast Cancer
patients led Zhang et al. (2009) to screen 365 Nigerian
women with Breast cancer and 177 controls for this mu-
tation. This genetic mutation was further discovered in 3
other unrelated patients. All the patients were of the
Yoruba ethnic group.
Masri et al. (2002) studied 20 unselected breast cancer
patients in Sudan. They analysed Exon 11 of the BRCA2
gene and exon 5–9 of the p53 codon. Four of the
patients had a family history of Breast carcinoma, while
1 of the patients – with a family history – had bilateral
disease. They found only 1 somatic mutation and 1 poly-
morphism. They however did not elaborate on the type
of mutation and/or the base pairs involved.
Awadelkarim et al. (2007) studied 34 Early onset (< 40
years) and 1 Male Breast Cancer patient in central Sudan.
All the coding regions of BRCA1 and BRCA2 were
analysed. Majority of the patients (33/35) had mutations.
They found 5 truncating mutations (2 in BRCA1, 3 in
BRCA2) in 5 patients, one of which, (BRCA2) was in the
male patient. They also found 55 unclassified variants (30
in BRCA1, 25 in BRCA2), 5 of which were predicted to
affect protein function.
Zhang et al. (2010) evaluated 352 patients from Nigeria
previously determined not to have any germline mutations
for either BRCA1 or BRCA2 for large genomic rear-
rangement (LGR). Multiplex ligation-dependent probe
amplification (MLPA) was used to screen BRCA1 rear-
rangements in these patients. They found only 1 patient
with a deletion of exon 21.
van der Merwe et al. (2010) screened 16 Black Xhosa
patients with breast cancer referred for genetic testing
for 6 founder mutations (3 Ashkenazi and 3 Afrikaner).
None of these patients carried any of these common
founder mutations. They found a mutation on exon 11
of the BRCA2 gene. They then went ahead to screen
exon 10 of BRCA1 and exon 10 & 11 of BRCA2. Four of
the Xhosa women were found to have a BRCA2 muta-
tion on exon 11. This mutation was also found to be
present in 4 out of 105 Colored patients referred for
genetic testing.North African (NA)
Balci et al. (1999) evaluated BRCA1 and BRCA2 in
Turkish breast and ovarian cancer patients with a strong
family history of breast cancer in 1999. The whole of the
genes were evaluated. In this group of 15 Families of 33
patients, three deleterious mutations (2 BRCA1 and 1
BRCA2) were detected. The BRCA2 mutation was de-
tected in one of the male breast cancer patients.
Ozdag et al. (2000) in 2000 published a study on 50
high risk Turkish Breast cancer patients. Patients were
selected based on four criteria; early age at onset, male
breast cancer, hereditary breast cancer and familial breast
cancer. Exons 2, 5, 11 (10 overlapping fragments), 13, 20
& 24 of BRCA1, and exon 11 (7 overlapping fragments) of
BRCA2 were analysed. Four deleterious mutations were
found. There were 2 (BRCA2) mutations in the patients
with hereditary breast cancer. The other 2 (BRCA1) muta-
tions were found in patients with early onset breast can-
cer. One of these patients had 2 mutant alleles. There was
no truncating mutation discovered in the male breast can-
cer group. There were 5 BRCA1 sequence variants detec-
ted in 23 other patients.
In another Turkish study, Yazici et al. (2000) found 8
BRCA1 and 2 BRCA2 mutations in 11 out of a cohort of
105 patients with breast or ovarian cancer. One (1) of
the mutations was found only in an ovarian cancer pa-
tient and will not be part of the summary. Half of the
patients had a family history while the remaining half
had early onset breast cancer (< 50 years). Their analysis
was initially limited to exon 11 of both genes and exon
10 of BRCA2. They also performed complete analysis of
the BRCA1 gene in a subset of 24 patients and found
further mutations in exons 14 and 20, one of which was
the Askenazi Jewish mutation 5382insC. This led them
to do a heteroduplex analysis of exons 2, 14 and 20 of
the BRCA1 gene in all the patients. There was a higher
incidence of BRCA mutations (7 BRCA1 and 1 BRCA2)
in patients with a family history. Five truncating mutations
were identified in exon 11 of both genes. The remaining
mutations were in exon 2, 14, 20 and intron 14.
Uhrhammer et al. (2008) performed a study to deter-
mine the contribution of BRCA1 mutations to breast
cancer in Algeria. The patient population (64) was se-
lected on account of a family history of Breast cancer
(13) and early onset Breast cancer (51) (< 38 yrs). They
evaluated the whole of the BRCA1 gene. A total of 7
deleterious mutations were found in 11 patients repre-
senting 9 families. One of these mutations was found in
a patient with early onset breast cancer and another pa-
tient with familial breast cancer. Another mutation was
found in 2 different families with familial breast cancer.
Troudi et al. (2007) in Tunisia studied 36 patients with
family history of breast or ovarian cancer. All of the
BRCA1 and BRCA2 genes were analyzed. They found 6
Table 2 Exon(s)/mutations evaluated
STUDY BRCA1 BRCA2
Yawitch 185delAG in exon 2, 4184del4, 943ins10 and 1832deI5 in exon




Zhang B Y101X (422 T[G), exon 7 NONE
Masri NONE Exon 11
Awadelkarim ALL ALL
Zhang J ALL NONE
Stoppa Lyonnet ?? ??
Van der Merwe 185delAG, 5382insC, 1493delC, 2760 G > T, Exon 10 Exon 10 & 11 , 6174delT, 8162delG
NORTH AFRICA
Balci
Ozdag et al. (2000) 2, 5,11 (10 overlapping fragments), 13, 20, 24 11 (7 overlapping fragments)
Yazici 2, 11, 14, 20 (ALL in a subset of patients) 10, 11
Uhrhammer et al. (2008) ALL NONE
Troudi et al. (2007) ALL ALL
Cherbal F (2010) ALL ALL
Mahfoudh et al. (2011) ALL
Table 1 Summary of number patients and studies
Study Total Pt Family Hx Young Control BRCA1 BRCA2
SUB-SAHARAN AFRICA
Yawitch 206 11 0 0 00 0
Gao 70 1 70 0 2 1
Fackenthal 39 1 39 74 1 0
Zhang B 365 UNSELECTED 177 1
Masri 20 4 1
Awadelkarim 35 (1Male) 34 0 2 3
Zhang J 352
Stoppa Lyonnet NI 1 1
Van der Merwe 16 16
TOTAL 752
NORTH AFRICA
Balci 33 33 (3 Male) 0 0 0 0
Ozdag 50(10 Male) 13 27 0
Yazici 105 53 52 0 7 2
Urhammer 64 13 51
Troudi 36 36
Cherbal 86
Mahfoudh et al. (2011) 24 4
TOTAL 398
GRAND TOTAL 1150
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Table 3 Mutation(s) detected





Van der Merwe NONE
Fackenthal et al. (2005) NONE
Yazici 2 185 insA
Cherbal F(2010) 2 Deletion of Exon 2
Cherbal et al. (2010) 3 c.83_84delTG
Cherbal et al. (2010) 5 c.181 T > G
Troudi et al. (2007) 5 330 dup A
Zhang B 7 Y101X (422 T[G) 3 365 (177)
Cherbal et al. (2010) 8 Deletion of Exon 8
Gao et al. (2000) 11 Q1090X Stop 1 70
Gao et al. (2000) 11 1742insG Frameshift 1 70




Ozdag 11 1201 insA
11 K654E
Troudi et al. (2007) 11 4160 delAG
11 2789 del G
Cherbal et al. (2010) 11 c.798_799delTT
Stoppa-Lyonnet et al. (1997) 11 926ins10 Frameshift 1 (?160)
Gao et al. (2000) 11 3034/6del4 Frameshift 1 70
Fackenthal et al. (2005) 11 3034/6 delACAA
Masri 11 Not Indicated
Yazici 14 4508delC
Int 14 IVS-14 + 1delG
Balci et al. (1999) 20 5382insC Stop
Yazici 20 5382insC
Troudi et al. (2007) 20 5385ins C
Zhang et al. (2010) 21 Deletion of Exon 21 1
Balci et al. (1999) 24 5622C – T Stop
Awadelkarim KD(2007) NI c.3999delT Stop (codon 1335)
Awadelkarim et al. (2007) c.4065_4068delTCAA Stop (codon 1364)
Uhrhammer et al. (2008) c.46_74del29
c.83_84delTG
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Troudi et al. (2007) 10 1537 del4
Cherbal et al. (2010) 10 c.1310_1313delAAGA
van der Merwe et al. (2010) 11 5999del4 (?Founder) Frameshift
Balci et al. (1999) 11 3414delTCAG Stop
Ozdag 11 3034 delAAAC
11 6880 insG
Yazici et al. (2000) 11 5295insA
Yazici et al. (2000) 11 6656delC
Troudi et al. (2007) 11 5909 ins A
Cherbal et al. (2010) 11 c.5722 5723delCT
Awadelkarim et al. (2007) c.3195_3198delTAAT Stop (codon 1075)
Awadelkarim et al. (2007) c.6406_6407delTT Stop (codon 2139)
Awadelkarim et al. (2007) c.8642_8643insTTTT Stop (codon 2907)
NI = Not Indicated, ∞? Same patient as Gao.
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in BRCA1 (5 patients) and the remainder were in
BRCA2 (2 patients). In addition to these mutations, nine
distinct unclassified sequence variants (8 in BRCA1 and
1 in BRCA2) and 16 distinct polymorphisms (12 in
BRCA1 and 4 in BRCA2) were identified.
Cherbal et al. (2010) studied 86 high risk individuals –
male breast cancer, strong family history of breast, ova-
rian and/or prostate cancers – from 70 families. All
the regions of the BRCA1 and BRCA2 genes were eval-
uated for mutations. Individuals were screened by High-
Resolution Melting (HRM) curve analysis followed by
direct sequencing. Samples for which no pathogenic mu-
tation was found were analyzed by MLPA. Three patho-
genic mutations in BRCA1 gene and two within BRCA2
gene were detected using PCR and HRM. Using MLPA, a
novel deletion of BRCA1 exon 2 and a deletion of BRCA1
exon 8 were identified in two patients with breast/ovarian
cancer and bilateral breast cancer, respectively. The muta-
tions occurred in 8 of 70 families.
Mahfoudh et al. (2011) studied 24 patients in 16 breast/
ovarian cancer families. All the coding regions of the
BRCA1 gene were analysed. Six families had four delete-
rious mutations one of which (IVS5 + 2insG) was novel.
Another of the mutations (916delTT) was noted in 3 ap-
parently unrelated families.
Tables 1, 2, 3 show a summary of the studies, the por-
tion(s) of the gene(s) evaluated in each study and the
mutation(s) detected.Discussion
Throughout the continent of Africa, over a seventeen
year period, 16 studies have evaluated 1150 patients for
mutations in the BRCA1 and/or BRCA2 genes in breast
cancer patients. Seven hundred and fifty two from SSA
and 398 from NA. Four studies evaluated parts of BRCA1
& 2 in 171 patients, 5 studies evaluated the whole of the
BRCA1 gene in 465 patients, 6 studies evaluated all the
regions of both genes in 299, while 2 studies evaluated
parts of BRCA1 in 571 and 1 study evaluated part of
BRCA2 in 20 patients.
In this period, the evaluation of genetic mutations in
African breast cancer patients has improved from the
anecdotal reports of Stoppa-Lyonnet and the evaluation
of specific mutations by Yawitch to the discovery of
LGRs by Zhang.
In the African breast cancer patients studied, LGRs were
found rarely. In some areas, LGRs were also rare in breast
and ovarian cancer families de la Hoya et al. (2006; Engert
et al. 2008). This contrasts with other areas of the world
where Genomic rearrangements account for more than
one-third of the brca1 mutations in northern Italian
breast/ovarian cancer families Montagna et al. (2003).
Conclusion
In spite of the lower age at presentation and more aggres-
sive nature of breast cancer in African patients and the as-
sociation of genetic mutations with breast cancer in young
women, there has been a paucity of studies evaluating the
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Evaluation of only 1,150 patients in a disease with a 5 year
prevalence of 302,310 at a rate of less than one (1) study
per year since the discovery of the BRCA gene is less than
adequate. Most of the studies did not evaluate all the cod-
ing regions of the genes. Some of them only examined ei-
ther BRCA1 or BRCA2. Some mutations were found and
documented. However, the clinical significance of some of
the germ line mutations identified and the clinical applica-
tion is yet to be confirmed. This is because these studies
were grossly underpowered to make any far reaching con-
clusion about the genetics of the African patient with
Breast Cancer. There is therefore a need to perform well
powered studies and population screening to determine
the impact of germ line mutations in the African Breast
Cancer patient.
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